Idorsia has a strong and visionary leadership team with the power and drive to create more remarkable innovations and more new medicines.
The Idorsia Executive Committee
Chief Executive Officer
Date of birth: 3 April 1955
Nationality: Swiss and French
Education: Medical degree in France; further training in pharmacology and physiology at the University of Montreal, Canada, and the University of California, San Francisco, US.
Professional background: Practicing cardiologist, 1980–1985. Head of Drug Discovery Group in the Cardiovascular Department of F. Hoffmann-La Roche, 1985–1997. Founder and CEO of Actelion 1999-2017.
Executive Vice President, Chief Scientific Officer
Date of birth: 27 December 1955
Nationality: Swiss and French
Education: MD, specialization in pediatrics and in neonatal intensive care, educated at the University of Nancy, France; further training in physiology and pharmacology at McGill University, Montreal, Canada, and at the University of California, San Francisco, US.
Professional background: Assistant professor, Neonatology. Scientific expert, leader of drug discovery projects, F. Hoffmann-La Roche Ltd. Founder and Head of Drug Discovery, Pharmacology & Preclinical Development, Actelion, 1997–2009. Chief scientific Officer of Actelion 2009-2017.
Officer of the Legion of Honour
Executive Vice President, Head of Global Clinical Development
Date of birth: 19 November 1956
Education: MD, pulmonologist and PhD in life science, Paris University, France.
Professional background: Merck Serono, Chief Medical Officer; Serono, Chief Medical Officer International; various executive positions at Astra, Fisons, Rhône-Poulenc Rorer, Glaxo Wellcome, GSK and Chiron. Head of Global Clinical Development for Actelion 2009-2017.
André C. Muller
Executive Vice President, Chief Financial Officer
Date of birth: 30 October 1963
Education: Master’s degree in Business Administration from EMLYON Business School, Lyon, France.
Professional background: From 1994 until 2011, held various financial positions at Pierre Fabre SA, an international pharmaceutical and dermo-cosmetic company, serving as CFO from 2002. CFO of Actelion 2013-2017.
Members of the Extended Leadership Team
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Date of birth: 7 September 1968
Education: Master’s degree in Business Administration, Monetary Economics and Corporate Law from the University of Zurich and Chartered Financial Analyst (CFA).
Professional background: Built a deep expertise and network in the area capital markets, while focusing on gaining an understanding for the pharmaceutical and biotechnology market. Stepping stones as sell-side analyst, buy-side analyst and fund manager include: Equity analyst for European Pharmaceuticals at Warburg Dillon Read (1997–1999) and analyst/ fund manager at Julius Baer (2000–2005). Senior financial analyst covering Swiss/European pharmaceutical/biotechnology stocks for Bank Leu (2005), Bank Sarasin (2006) and Bank Vontobel (2007). Team leader for Life Sciences Equity Research at Bank Vontobel (2008–2014). Head of Investor Relations & Corporate Communications for Actelion 2014-2017.
Senior Vice President, Head of Human Resources
Date of birth: 11 September 1978
Education: Master degree in Human Resources Management in Russia, Bachelor degree in Finance in Russia; further education and training in Business Administration and Communication in the US (California State University East Bay, Hayward) and in Coaching and Neuro-linguistic Programming in Erickson College, Vancouver, Canada.
Professional background: HR Manager and Organizational Development Manager at British American Tobacco in Russia and in Switzerland 2003-2007; HR Director for Global Clinical Development and Head of Global Talent Acquisition and Development at Actelion 2007-2017. As of 2013 practicing independent professional coach.
Senior Vice President, Group General Counsel
Date of birth: 20 February 1970
Education: J.D. from the University of Bern, Switzerland. Admission to the Bar of the Canton of Bern.
Professional Background: Legal Counsel for transactions and litigation 2000-2007 in a telecommunications company, 2007-2017 Associate General Counsel and Deputy Group Compliance Officer at Actelion.
Senior Vice President, Head of Pharmaceutical Development
Date of birth: 16 December 1966
Education: Ph.D. in applied Physico-Chemistry (polymer sciences) in France.
Professional background: 1998–2005. Principal Scientist and Technology Matrix Leader for Parenteral Sustained Delivery systems in the Pharmaceutical Department of Novartis Pharma AG, 2005-2013 CMC project leader at Actelion Pharmaceuticals Ltd, 2013 - 2017 Head Quality Assurance (GMP/GDP) at Actelion Pharmaceuticals Ltd.
Senior Vice President, Head of Drug Discovery Chemistry
Date of birth: 20 June 1954
Education: PhD, organic chemistry at the ETH Zurich, Switzerland with post-doctoral training at Columbia University New York, USA.
Professional background: Research chemist 1983-1986, Group leader 1986-1994, Area head of chemistry in thrombosis/arteriosclerosis research 1994-1999, F. Hoffmann-La Roche Ltd. Head of Drug Discovery, Chemistry, Actelion, 1999–2017.
Markus A. Riederer
Senior Vice President, Head of Drug Discovery Biology
Date of birth: 14 January 1962
Education: Doctoral degree. Dr. Phil.II at the University of Basel, Switzerland, further education at Stanford University, Shool of Medicine, Stanford, CA, US.
Professional background: Research Scientist, Thrombosis Group at Hoffmann-La Roche, 1994-1997. Project Leader “Novel Oral Anticoagulant Project” at Hoffmann-La Roche, 1997-2002. Head of Biology, Axovan Pharmaceutical, 2002-2003. Senior Group Leader, Immunology/Thrombosis Biology at Actelion Pharmaceuticals Ltd, 2003-2016. Head DD Biology, at Actelion Pharmaceuticals Ltd, 2016-2017.
Senior Vice President, Head of Drug Discovery Pharmacology & Preclinical Development
Date of birth: 1 April 1967
Education: PhD in Biochemistry/Life Sciences, Universities of Kaiserslautern and Frankfurt, Msc Toxicology, University of Surrey, UK
Professional background: From 1993 until 2004, various positions in project toxicology/drug development at Sandoz, Ciba and F. Hoffmann-La Roche, 2004-2017 Head of Toxicology, Actelion, since 2011 Head of Preclinical Development, Actelion